{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:29:03Z","timestamp":1780824543375,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the Ebola virus disease (EVD) epidemic in Western Africa (2013\u20122016), antimalarial treatment was administered to EVD patients due\u00a0to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine. As artemether and artesunate are derivatives of artemisinin, the beneficial anti-Ebola virus (EBOV) effect observed could possibly be attributed to the change from lumefantrine to amodiaquine. Amodiaquine is a widely used antimalarial in the countries that experience outbreaks of EVD and, therefore, holds promise as an approved drug that could be repurposed for treating EBOV infections. We investigated the potential anti-EBOV effect of amodiaquine in a well-characterized nonhuman primate model of EVD. Using a similar 3-day antimalarial dosing strategy as for human patients, plasma concentrations of amodiaquine in healthy animals were similar to those found in humans. However, the treatment regimen did not result in a survival benefit or decrease of disease signs in EBOV-infected animals. While amodiaquine on its own failed to demonstrate efficacy, we cannot exclude potential therapeutic value of amodiaquine when used in combination with artesunate or another antiviral.<\/jats:p>","DOI":"10.1038\/s41598-019-56481-0","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T11:02:42Z","timestamp":1577444562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["In Vivo Activity of Amodiaquine against Ebola Virus Infection"],"prefix":"10.1038","volume":"9","author":[{"given":"Lisa Evans","family":"DeWald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Torzewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Postnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-148X","authenticated-orcid":false,"given":"Anna N.","family":"Honko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Janosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Huzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Eakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire L.","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Gahagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon C.","family":"Mirsalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-2667","authenticated-orcid":false,"given":"Michael R.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jahrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9856-4183","authenticated-orcid":false,"given":"Julie","family":"Dyall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"56481_CR1","unstructured":"World Health Organization. Clinical management of patients with viral haemorrhagic fever, https:\/\/www.who.int\/csr\/resources\/publications\/clinical-management-patients\/en\/ (2016)."},{"key":"56481_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504605","volume":"374","author":"E Gignoux","year":"2016","unstructured":"Gignoux, E. et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N Engl J Med 374, 23\u201332, https:\/\/doi.org\/10.1056\/NEJMoa1504605 (2016).","journal-title":"N Engl J Med"},{"key":"56481_CR3","doi-asserted-by":"publisher","first-page":"ofz250","DOI":"10.1093\/ofid\/ofz250","volume":"6","author":"SC Garbern","year":"2019","unstructured":"Garbern, S. C. et al. Effect of Mass Artesunate-Amodiaquine Distribution on Mortality of Patients With Ebola Virus Disease During West African Outbreak. Open Forum Infect Dis 6, ofz250, https:\/\/doi.org\/10.1093\/ofid\/ofz250 (2019).","journal-title":"Open Forum Infect Dis"},{"key":"56481_CR4","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/jac\/dku091","volume":"69","author":"G Gehring","year":"2014","unstructured":"Gehring, G. et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 69, 2123\u20132131, https:\/\/doi.org\/10.1093\/jac\/dku091 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"56481_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.88","volume":"3","author":"J Kouznetsova","year":"2014","unstructured":"Kouznetsova, J. et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3, e84, https:\/\/doi.org\/10.1038\/emi.2014.88 (2014).","journal-title":"Emerg Microbes Infect"},{"key":"56481_CR6","doi-asserted-by":"publisher","first-page":"e60579","DOI":"10.1371\/journal.pone.0060579","volume":"8","author":"PB Madrid","year":"2013","unstructured":"Madrid, P. B. et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 8, e60579, https:\/\/doi.org\/10.1371\/journal.pone.0060579 (2013).","journal-title":"PLoS One"},{"key":"56481_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","volume":"1","author":"PB Madrid","year":"2015","unstructured":"Madrid, P. B. et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 1, 317\u2013326, https:\/\/doi.org\/10.1021\/acsinfecdis.5b00030 (2015).","journal-title":"ACS Infect Dis"},{"key":"56481_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep13476","volume":"5","author":"L Zilbermintz","year":"2015","unstructured":"Zilbermintz, L. et al. Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Sci Rep 5, 13476, https:\/\/doi.org\/10.1038\/srep13476 (2015).","journal-title":"Sci Rep"},{"key":"56481_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1086\/591195","volume":"47","author":"T Efferth","year":"2008","unstructured":"Efferth, T. et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 47, 804\u2013811, https:\/\/doi.org\/10.1086\/591195 (2008).","journal-title":"Clin Infect Dis"},{"key":"56481_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/82_2017_20","volume":"411","author":"RS Bennett","year":"2017","unstructured":"Bennett, R. S. et al. Nonhuman Primate Models of Ebola Virus Disease. Curr Top Microbiol Immunol 411, 171\u2013193, https:\/\/doi.org\/10.1007\/82_2017_20 (2017).","journal-title":"Curr Top Microbiol Immunol"},{"key":"56481_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7, 27\u201331, https:\/\/doi.org\/10.4103\/0976-0105.177703 (2016).","journal-title":"J Basic Clin Pharm"},{"key":"56481_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00228-007-0452-8","volume":"64","author":"C Orrell","year":"2008","unstructured":"Orrell, C. et al. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 64, 683\u2013690, https:\/\/doi.org\/10.1007\/s00228-007-0452-8 (2008).","journal-title":"Eur J Clin Pharmacol"},{"key":"56481_CR13","doi-asserted-by":"publisher","first-page":"S672","DOI":"10.1093\/infdis\/jiy304","volume":"218","author":"J Dyall","year":"2018","unstructured":"Dyall, J. et al. Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures. J Infect Dis 218, S672\u2013S678, https:\/\/doi.org\/10.1093\/infdis\/jiy304 (2018).","journal-title":"J Infect Dis"},{"key":"56481_CR14","doi-asserted-by":"publisher","first-page":"290ra289","DOI":"10.1126\/scitranslmed.aaa5597","volume":"7","author":"LM Johansen","year":"2015","unstructured":"Johansen, L. M. et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med 7, 290ra289, https:\/\/doi.org\/10.1126\/scitranslmed.aaa5597 (2015).","journal-title":"Sci Transl Med"},{"key":"56481_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/2040206617740303","volume":"25","author":"M Baba","year":"2017","unstructured":"Baba, M. et al. Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors. Antivir Chem Chemother 25, 83\u201389, https:\/\/doi.org\/10.1177\/2040206617740303 (2017).","journal-title":"Antivir Chem Chemother"},{"key":"56481_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.antiviral.2016.11.015","volume":"137","author":"A Balasubramanian","year":"2017","unstructured":"Balasubramanian, A., Teramoto, T., Kulkarni, A. A., Bhattacharjee, A. K. & Padmanabhan, R. Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antiviral Res 137, 141\u2013150, https:\/\/doi.org\/10.1016\/j.antiviral.2016.11.015 (2017).","journal-title":"Antiviral Res"},{"key":"56481_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.antiviral.2014.03.014","volume":"106","author":"S Boonyasuppayakorn","year":"2014","unstructured":"Boonyasuppayakorn, S., Reichert, E. D., Manzano, M., Nagarajan, K. & Padmanabhan, R. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res 106, 125\u2013134, https:\/\/doi.org\/10.1016\/j.antiviral.2014.03.014 (2014).","journal-title":"Antiviral Res"},{"key":"56481_CR18","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1128\/AAC.03036-14","volume":"58","author":"J Dyall","year":"2014","unstructured":"Dyall, J. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58, 4885\u20134893, https:\/\/doi.org\/10.1128\/AAC.03036-14 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"56481_CR19","doi-asserted-by":"publisher","unstructured":"Hulseberg, C. E. et al. Arbidol and other low molecular weight drugs that inhibit Lassa and Ebola viruses. J Virol, https:\/\/doi.org\/10.1128\/JVI.02185-18 (2019).","DOI":"10.1128\/JVI.02185-18"},{"key":"56481_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14787210.2017.1305888","volume":"15","author":"C Salata","year":"2017","unstructured":"Salata, C., Calistri, A., Parolin, C., Baritussio, A. & Palu, G. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther 15, 483\u2013492, https:\/\/doi.org\/10.1080\/14787210.2017.1305888 (2017).","journal-title":"Expert Rev Anti Infect Ther"},{"key":"56481_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12688\/f1000research.5741.2","volume":"3","author":"S Ekins","year":"2014","unstructured":"Ekins, S., Freundlich, J. S. & Coffee, M. A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Res 3, 277, https:\/\/doi.org\/10.12688\/f1000research.5741.2 (2014).","journal-title":"F1000Res"},{"key":"56481_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.antiviral.2018.10.025","volume":"160","author":"Y Sakurai","year":"2018","unstructured":"Sakurai, Y., Sakakibara, N., Toyama, M., Baba, M. & Davey, R. A. Novel amodiaquine derivatives potently inhibit Ebola virus infection. Antiviral Res 160, 175\u2013182, https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.025 (2018).","journal-title":"Antiviral Res"},{"key":"56481_CR23","first-page":"721","volume-title":"Br Med J (Clin Res Ed)","author":"KA Neftel","year":"1986","unstructured":"Neftel, K. A., Woodtly, W., Schmid, M., Frick, P. G. & Fehr, J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 292, (721\u2013723 (1986)."},{"key":"56481_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-250","volume":"12","author":"B Schramm","year":"2013","unstructured":"Schramm, B. et al. Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia. Malar J 12, 250, https:\/\/doi.org\/10.1186\/1475-2875-12-250 (2013).","journal-title":"Malar J"},{"key":"56481_CR25","doi-asserted-by":"publisher","first-page":"e0166318","DOI":"10.1371\/journal.pone.0166318","volume":"11","author":"Y Cong","year":"2016","unstructured":"Cong, Y. et al. Evaluation of the activity of lamivudine and zidovudine against Ebola virus. PLoS One 11, e0166318, https:\/\/doi.org\/10.1371\/journal.pone.0166318 (2016).","journal-title":"PLoS One"},{"key":"56481_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06179-y","volume":"7","author":"AN Honko","year":"2017","unstructured":"Honko, A. N. et al. High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. Sci Rep 7, 5886, https:\/\/doi.org\/10.1038\/s41598-017-06179-y (2017).","journal-title":"Sci Rep"},{"key":"56481_CR27","first-page":"298","volume":"4","author":"P Vogel","year":"1997","unstructured":"Vogel, P. et al. Pathology of experimental Ebola-Zaire (Mayinga) virus infection transmitted to guinea pigs by oral, conjunctival and tonsillar routes. Cell Vis 4, 298\u2013307 (1997).","journal-title":"Cell Vis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56481-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:12:19Z","timestamp":1671300739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56481"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56481-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20199"}}